ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors
-- Partnership combines ArsenalBio’s programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development --
-- ArsenalBio employs a suite of proprietary technologies to encode synthetic biological instructions to overcome solid tumors’ complex defense systems --
Through the multi-year collaboration, ArsenalBio will deploy its full stack of synthetic biology compositions to build programmable cell therapy product candidates, composed of its PrimeR™ logic gates, CARchitecture™ derived gene expression controls, and CellFoundry™ mediated nonviral manufacturing. Combined, these integrated circuit-modified T cells offer the promise of improved outcomes for patients.
“Despite the therapeutic benefit of cell therapies for hematologic cancers, cell therapies for solid tumors remain an area of significant opportunity and unmet medical need,” said
Under the terms of the agreement,
ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy by helping more patients fight cancer and saving lives. Our discovery engine comprises the CellFoundry™ based nonviral manufacturing, integrated circuits comprised of PrimeR™ logic gates and CAR enhancements from our CARchitecture™ library, enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Visit us at www.arsenalbio.com to learn more.